005500 — Samjin Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapNeutral

Annual income statement for Samjin Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	250,070	274,032	292,129	308,350	309,134
Cost of Revenue
Gross Profit	117,832	117,734	116,681	128,967	125,084
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	216,120	250,065	271,628	276,822	282,384
Operating Profit	33,951	23,967	20,501	31,528	26,750
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	34,911	25,226	15,557	43,642	22,098
Provision for Income Taxes
Net Income After Taxes	28,404	21,901	18,906	39,233	24,170
Minority Interest
Net Income Before Extraordinary Items
Net Income	28,404	21,894	18,908	39,233	24,170
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	28,404	21,894	18,908	39,233	24,170
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2,238	1,640	1,450	3,123	1,962
Dividends per Share